Stock SLRN ACELYRIN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Acelyrin, Inc.

Equities

SLRN

US00445A1007

Market Closed - Nasdaq
Other stock markets
 21:00:00 24/06/2024 BST 		5-day change 1st Jan Change
4.03 USD -1.23% Intraday chart for Acelyrin, Inc. -4.28% -45.98%
06-05 Transcript : Acelyrin, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:00 PM
06-05 ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Efficacy and Safety of Izokibep, a Novel IL 17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 16 Results from a Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2b/3 Study
PU
Transcript : Acelyrin, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 01:00 PM
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
GL
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
AQ
ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024
CI
Acelyrin : Preliminary Safety And Efficacy Of Subcutaneous Lonigutamab (anti IGF 1R) From A Phase 1/2 Proof Of Concept Study In Patients With Thyroid Eye Disease
PU
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
GL
HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating
MT
Acelyrin, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024
CI
ACELYRIN, INC. Announces Leadership Transition
GL
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
GL
Acelyrin, Inc. Announces CEO Changes
CI
Acelyrin, Inc. Announces Leadership Transition
CI
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
GL
Affibody publishes Annual Report 2023
AQ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited
DJ
Acelyrin, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
GL
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLRN Stock
  4. News Acelyrin, Inc.